Replies to post #135278 on Biotech Values

[genisi]

We're on the same wavelength about regorafenib clinical relevance #msg-71008932

[vinmantoo]

Overall survival is the metric that won approval for Nexavar in HCC, not PFS. Regorafenib appears to be following that pattern, so I think the focus on the small but not statistically significant increase in PFS for Regorafenib is misplaced.

[DewDiligence]

Erbitux fails to improve DFS when added to chemo in adjuvant (post-surgical) CRC:

http://in.reuters.com/article/2012/05/09/us-merck-idINBRE8480C820120509